Chia-Hsien Wu

Dr. Chia-Hsien Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
SHSho Hasegawa
Sho Hasegawa
TITsuyoshi Inoue
Tsuyoshi Inoue
YNYasuna Nakamura
Yasuna Nakamura
DFDaichi Fukaya
Daichi Fukaya
RURie Uni
Rie Uni
RIReiko Inagi
Reiko Inagi
Significance Statement: The detailed role of neural activity in inflammatory diseases is still unclear because it varies according to the disease situation and responsible cell types. This study shows that activation of β2-adrenergic receptor (Adrb2) signaling in macrophages induces the expression of T cell Ig and mucin domain 3 (Tim3), which contributes to anti-inflammatory phenotypic alterations. Experiments using conditional knockout mice reveal that macrophage Adrb2 signaling directly mitigates LPS-induced systemic inflammation and renal ischemia-reperfusion injury (IRI). The adoptive transfer of Adrb2 signal–activated macrophages also protects against renal IRI, in association with the accumulation of Tim3-expressing macrophages in the renal tissue. These results indicate that macrophage Adrb2 signaling plays critical roles in the severity of AKI. Background: The sympathetic nervous system regulates immune cell dynamics. However, the detailed role of sympathetic signaling in inflammatory diseases is still unclear because it varies according to the disease situation and responsible cell types. This study focused on identifying the functions of sympathetic signaling in macrophages in LPS-induced sepsis and renal ischemia-reperfusion injury (IRI). Methods: We performed RNA sequencing of mouse macrophage cell lines to identify the critical gene that mediates the anti-inflammatory effect of β2-adrenergic receptor (Adrb2) signaling. We also examined the effects of salbutamol (a selective Adrb2 agonist) in LPS-induced systemic inflammation and renal IRI. Macrophage-specific Adrb2 conditional knockout (cKO) mice and the adoptive transfer of salbutamol-treated macrophages were used to assess the involvement of macrophage Adrb2 signaling. Results: In vitro, activation of Adrb2 signaling in macrophages induced the expression of T cell Ig and mucin domain 3 (Tim3), which contributes to anti-inflammatory phenotypic alterations. In vivo, salbutamol administration blocked LPS-induced systemic inflammation and protected against renal IRI; this protection was mitigated in macrophage-specific Adrb2 cKO mice. The adoptive transfer of salbutamol-treated macrophages also protected against renal IRI. Single-cell RNA sequencing revealed that this protection was associated with the accumulation of Tim3-expressing macrophages in the renal tissue. Conclusions: The activation of Adrb2 signaling in macrophages induces anti-inflammatory phenotypic alterations partially via the induction of Tim3 expression, which blocks LPS-induced systemic inflammation and protects against renal IRI.

Verified
Journal Article
Open access
PDF file
JCJia Huang Chen
Jia Huang Chen
CWChia-Hsien Wu
Chia-Hsien Wu
CCChih-Kang Chiang
Chih-Kang Chiang
Pathological insults usually disturb the folding capacity of cellular proteins and lead to the accumulation of misfolded proteins in the endoplasmic reticulum (ER), which leads to so-called “ER stress”. Increasing evidence indicates that ER stress acts as a trigger factor for the development and progression of many kidney diseases. The unfolded protein responses (UPRs), a set of molecular signals that resume proteostasis under ER stress, are thought to restore the adaptive process in chronic kidney disease (CKD) and renal fibrosis. Furthermore, the idea of targeting UPRs for CKD treatment has been well discussed in the past decade. This review summarizes the up-to-date literature regarding studies on the relationship between the UPRs, systemic fibrosis, and renal diseases. We also address the potential therapeutic possibilities of renal diseases based on the modulation of UPRs and ER proteostasis. Finally, we list some of the current UPR modulators and their therapeutic potentials.

28 June 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
AYAobing Yang
Aobing Yang
CWChia-Hsien Wu
Chia-Hsien Wu
SMSayumi Matsuo
Sayumi Matsuo
RURyusuke Umene
Ryusuke Umene
YNYasuna Nakamura
Yasuna Nakamura
TITsuyoshi Inoue
Tsuyoshi Inoue

27 December 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CWChia-Hsien Wu
Chia-Hsien Wu
TITsuyoshi Inoue
Tsuyoshi Inoue
YNYasuna Nakamura
Yasuna Nakamura
RURie Uni
Rie Uni
SHSho Hasegawa
Sho Hasegawa
RIReiko Inagi
Reiko Inagi

24 April 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JPJoseph Kasyoki Peter
Joseph Kasyoki Peter
RURyusuke Umene
Ryusuke Umene
CWChia-Hsien Wu
Chia-Hsien Wu
YNYasuna Nakamura
Yasuna Nakamura
NWNorito Washimine
Norito Washimine
TITsuyoshi Inoue
Tsuyoshi Inoue

2 May 2023 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
RURyusuke Umene
Ryusuke Umene
YNYasuna Nakamura
Yasuna Nakamura
CWChia-Hsien Wu
Chia-Hsien Wu
KMKumiko Muta
Kumiko Muta
TNTomoya Nishino
Tomoya Nishino
TITsuyoshi Inoue
Tsuyoshi Inoue